Analysts have been eager to weigh in on the Healthcare sector with new ratings on Charles River Labs (CRL – Research Report), Plus Therapeutics (PSTV – Research Report) and Argenx Se (ARGX – Research Report).
Charles River Labs (CRL)
Jefferies analyst David Windley assigned a Hold rating to Charles River Labs yesterday and set a price target of $226.00. The company’s shares closed last Thursday at $230.09.
According to TipRanks.com, Windley is a 5-star analyst with an average return of
Currently, the analyst consensus on Charles River Labs is a Moderate Buy with an average price target of $269.10.
See Insiders’ Hot Stocks on TipRanks >>
Plus Therapeutics (PSTV)
In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Plus Therapeutics, with a price target of $32.00. The company’s shares closed last Thursday at $2.24.
According to TipRanks.com, Walsh is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Plus Therapeutics with a $18.00 average price target.
Argenx Se (ARGX)
In a report released yesterday, Akash Tewari from Jefferies assigned a Buy rating to Argenx Se, with a price target of $499.00. The company’s shares closed last Thursday at $382.55.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Currently, the analyst consensus on Argenx Se is a Moderate Buy with an average price target of $473.51, which is a 24.5% upside from current levels. In a report issued on April 26, Piper Sandler also maintained a Buy rating on the stock with a $522.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRL:
- Charles River backs FY24 EPS view $10.90-$11.40, consensus $11.02
- Charles River reports Q1 EPS $2.27, consensus $2.07
- CRL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Charles River announces rare disease gene therapy collaboration with Axovia
- Charles River to perform plasmid production for Ship of Theseus
